Dexcom (DXCM): analysis and statistics
Return, volatility, Sharpe ratio and risk for Dexcom, an S&P 500 component in the Health Care sector. Data as of 2026-07-30.
| Last close price | $74.54 |
| Sector (GICS) | Health Care |
| Annualized return (3.0 yr) | -15.81% |
| Total return over period | -40.16% |
| Annualized volatility | 47.43% |
| Sharpe ratio | -0.41 |
| Sortino ratio | -0.53 |
| Max drawdown | -60.95% |
| CVaR 95% (avg. loss, worst 5% of days) | -6.92% |
| Correlation with the S&P 500 | 0.27 |
| Period range | $54.84 – $140.45 |
| Trading days analyzed | 752 |
Over the last 3.0 years, Dexcom (DXCM) has posted an annualized return of -15.81% with annual volatility of 47.43%, a negative Sharpe ratio: over this period it did not beat the risk-free Treasury rate. Its worst stretch (max drawdown from a peak) was -60.95%. Its correlation with the S&P 500 is 0.27, which means it moves fairly independently of the index, useful for diversification.
These are historical, realized metrics, not projections: they describe how the stock behaved, not how it will behave going forward. To see how DXCM would fit inside an optimized portfolio alongside other S&P 500 stocks, try the optimizer.
Optimize a portfolio with DXCM →
Other Health Care stocks
What is the Sharpe ratio? · How to optimize an S&P 500 portfolio